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Eﬀ ectiveness of thigh-length graduated compression stockings 
to reduce the risk of deep vein thrombosis after stroke 
(CLOTS trial 1): a multicentre, randomised controlled trial
The CLOTS Trials Collaboration*
Summary
Background Deep vein thrombosis (DVT) and pulmonary embolism are common after stroke. In small trials of 
patients undergoing surgery, graduated compression stockings (GCS) reduce the risk of DVT. National stroke 
guidelines extrapolating from these trials recommend their use in patients with stroke despite insuﬃ  cient evidence. 
We assessed the eﬀ ectiveness of thigh-length GCS to reduce DVT after stroke. 
Methods In this outcome-blinded, randomised controlled trial, 2518 patients who were admitted to hospital within 
1 week of an acute stroke and who were immobile were enrolled from 64 centres in the UK, Italy, and Australia. 
Patients were allocated via a central randomisation system to routine care plus thigh-length GCS (n=1256) or to 
routine care plus avoidance of GCS (n=1262). A technician who was blinded to treatment allocation undertook 
compression Doppler ultrasound of both legs at about 7–10 days and, when practical, again at 25–30 days after 
enrolment. The primary outcome was the occurrence of symptomatic or asymptomatic DVT in the popliteal or femoral 
veins. Analyses were by intention to treat. This study is registered, number ISRCTN28163533.
Findings All patients were included in the analyses. The primary outcome occurred in 126 (10·0%) patients allocated to 
thigh-length GCS and in 133 (10·5%) allocated to avoid GCS, resulting in a non-signiﬁ cant absolute reduction in risk of 
0·5% (95% CI –1·9% to 2·9%). Skin breaks, ulcers, blisters, and skin necrosis were signiﬁ cantly more common in 
patients allocated to GCS than in those allocated to avoid their use (64 [5%] vs 16 [1%]; odds ratio 4·18, 95% CI 
2·40–7·27).
Interpretation These data do not lend support to the use of thigh-length GCS in patients admitted to hospital with 
acute stroke. National guidelines for stroke might need to be revised on the basis of these results.
Funding Medical Research Council (UK), Chief Scientist Oﬃ  ce of Scottish Government, Chest Heart and Stroke 
Scotland, Tyco Healthcare (Covidien) USA, and UK Stroke Research Network.
Introduction
Deep vein thrombosis (DVT) and pulmonary embolism 
(PE) are common complications of admission to hospital 
for surgery or acute medical problems, and result in many 
avoidable deaths.1 These complications emphasise the 
potential importance of measures that might reduce the 
risk of venous thromboembolism, such as anti coagulation, 
external compression with graduated compression 
stockings (GCS), and intermittent pneumatic com-
pression. Up to 42% of patients admitted with stroke 
develop venous thromboembolism.2 Although use of anti-
coagulants reduces this risk, the associated excess of 
intracranial and extracranial haemorrhages largely oﬀ sets 
any beneﬁ t.3 Thus, most national stroke guidelines do not 
recommend routine use of anticoagulants in ischaemic 
stroke, but instead recommend the use of GCS.4–12 However, 
guidelines vary considerably, with some recommending 
anticoagulation and only GCS in patients unsuitable for 
anti coagulation, and others recommending routine 
stocking use but avoidance of anticoagulants. The UK 
National Institute for Health and Clinical Excellence 
(NICE) has recently drafted guidelines for reducing the 
risk of venous thromboembolism which included the 
recommendation: “For patients diagnosed with stroke, 
oﬀ er mechanical VTE prophylaxis (thigh-length anti-
embolism stockings, inter mittent pneumatic com pression 
devices or foot impulse devices) from admission until the 
patient’s mobility is no longer increasing or until 
discharge”.13 
A systematic review14 identiﬁ ed 17 single-centre random-
ised controlled trials in patients admitted to hospital in 
which 2412 patients or legs were randomly assigned to 
GCS or control. GCS was associated with a 63% (95% CI 
52–70) reduction in the odds of (mainly distal) DVT. 15 of 
the 17 trials were in surgical patients, one was in acute 
medical patients (n= 80).15 Only one trial was in patients 
with stroke16 and in this trial, seven of 65 patients (10·8%) 
allocated GCS and seven of 32 (21·9%) allocated to avoid 
GCS had DVTs detected on Doppler ultrasound within 
10 days of enrolment (odds ratio 0·43, 95% CI 0·14–1·36). 
14 of the 17 trials tested thigh-length GCS, two tested 
below-knee GCS and, in one, the length was not speciﬁ ed. 
A systematic review of external compression speciﬁ cally in 
stroke17 did not identify any other randomised controlled 
trials investigating GCS. For patients with stroke, unlike 
surgical patients, external compression cannot be applied 
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before the patient is immobilised. In stroke, leg paralysis 
and immobility can persist for weeks or months, rather 
than hours or days. Additionally, patients with stroke 
have a high risk of concomitant peripheral vascular 
disease and diabetes, which potentially increases the risk 
of ischaemic skin damage to the legs resulting from 
external compression.18,19
The CLOTS (Clots in Legs Or sTockings after Stroke) 
trials are three multicentre randomised controlled trials 
that use the same randomisation, data collection, and 
follow-up systems and that aim to assess the balance of 
risk and beneﬁ t of external compression in patients with 
acute stroke. All three trials test the eﬀ ect of the addition 
of diﬀ erent compression strategies to routine care. The 
CLOTS trial 1, reported here, tested thigh-length GCS 
versus avoidance of GCS. The CLOTS trials 2 and 3 are 
in progress and are testing thigh-length GCS versus 
below-knee GCS, and intermittent pneumatic com-
pression versus avoidance of intermittent pneumatic 
compression, respectively.
Methods
Study design and patients
CLOTS trial 1 is a pragmatic, multicentre, international, 
outcome-blinded, randomised controlled trial. Between 
March 7, 2001, and Nov 27, 2008, patients were enrolled 
in 55 centres in the UK, seven in Italy, and two in 
Australia. Patients who were admitted to hospital 
within 1 week of an acute stroke and who were immobile 
(deﬁ ned as being unable to walk independently to the 
toilet) were eligible for inclusion and could be randomised 
between the day of admission (day 0) up to day 3. We 
excluded patients with peripheral vascular disease, and 
those with diabetic or sensory neuropathy, when the 
responsible clinician or nurse judged that GCS might 
cause skin damage. Patients with stroke due to 
subarachnoid haemorrhage were also excluded.
The protocol was approved by the multicentre research 
ethics committees (in Scotland, reference 00/0/28; and 
England, reference 07/H0907/178) and by the local ethics 
committees of all contributing centres. We obtained 
2518 patients enrolled and randomised
1256 allocated to thigh-length GCS 1262 allocated to avoid GCS
1217 compliant with allocation
916 wore thigh-length GCS until death/discharge/mobile/30 days
 or later second CDU
1192 compliant with allocation
42 wore thigh-length GCS until death/discharge/mobile/30 days
 or later second CDU
67 died before any CDU
1138 ﬁrst screening CDU completed
35 at <7 days
932 at 7–10 days (per protocol)
171 at >10 days
51 ﬁrst screening CDU missing
11 missing because too ill
18 missing because patient refused
22 missing due to administrative or other problem
90 died before planned second screening CDU
351 second CDU screening not planned
9 no second CDU because previous primary outcome
700 second screening CDU completed
24 at <25 days
527 at 25–30 days (per protocol)
149 at >30 days
106 second screening CDU missing
15 missing because too ill
54 missing because patient refused
37 missing due to administrative or other problem
1252 discharge form returned (after hospital discharge or death)
1256 vital status at 30 days known and assessed
117 post-randomisation prophylactic dose heparin/LMWH prescribed
78 post-randomisation treatment dose heparin/LMWH prescribed
186 post-randomisation warfarin prescribed
1260 discharge form returned (after hospital discharge or death)
1262 vital status at 30 days known and assessed
129 post-randomisation prophylactic dose heparin/LMWH prescribed
97 post-randomisation treatment dose heparin/LMWH prescribed
208 post-randomisation warfarin prescribed
82 died before planned second screening CDU
330 second CDU screening not planned
8 no second CDU because previous primary outcome
756 second screening CDU completed
20 at <25 days
582 at 25–30 days (per protocol)
154 at >30 days
86 second screening CDU missing
16 missing because too ill
26 missing because patient refused
44 missing due to administrative or other problem
44 died before any CDU
1179 ﬁrst screening CDU completed
50 at <7 days
939 at 7–10 days (per protocol)
190 at >10 days
39 ﬁrst screening CDU missing
15 missing because too ill
8 missing because patient refused
16 missing due to administrative or other problem
Figure 1: Trial proﬁ le
The number screened for eligibility was not collected. GCS=graduated compression stockings. CDU=compression Doppler ultrasound. 
LMWH=low-molecular-weight heparin.
Articles
1960 www.thelancet.com   Vol 373   June 6, 2009
written informed consent from all patients, or for patients 
without mental capacity, a valid proxy. 
Procedures
Having identiﬁ ed an eligible patient, the clinician 
completed a randomisation form. The clinician entered 
the patient’s baseline data via a web-based or a 24-h 
telephone randomisation service. After the baseline data 
had been entered and the computer program had 
checked for completeness and consistency, the system 
generated a group allocation—either routine care plus 
thigh-length GCS (Tyco Healthcare [Covidien], MA, 
USA) or routine care plus avoidance of GCS. We used a 
minimisation program to achieve optimum balance 
within centres for key prognostic factors: delay since 
stroke onset (day 0 or 1 vs day ≥2); stroke severity with a 
validated prognostic model;20 leg paresis (able or not to 
lift both legs oﬀ  the bed); and prescription of heparin, 
warfarin, or alteplase. Because simple minimisation 
within centres can lead to alternation of treatment 
allocation and thus potential loss of allocation 
concealment, our system also incorporated a degree of 
random allocation—ie, patients were allocated to the 
treatment group that would minimise the diﬀ erence 
between the groups with a probability of 0·80.
For patients allocated to thigh-length GCS, stockings 
were to be applied to both legs as soon as possible after 
randomisation and then worn day and night until either 
the patient was independently mobile around the ward; 
they were discharged from the recruiting centre; the 
patient refused to wear them; or the staﬀ  became 
concerned about the patient’s skin. We asked centres to 
record their use of GCS on the medication chart in the 
same way as for prescribed drugs to help increase 
compliance and to help with monitoring. The date of, 
and reason for, early removal of GCS was collected. 
Patients allocated to avoid GCS were not to be ﬁ tted with 
stockings unless a clear indication for their use developed. 
Both groups were to be given the same routine care that 
could have included, depending on local protocols, early 
mobilisation, hydration, and antiplatelet and anti-
coagulant drugs. We monitored antiplatelet and 
anticoagulant use throughout follow-up.
The primary outcome was a deﬁ nite or probable 
symptomatic or asymptomatic DVT in the popliteal or 
femoral veins detected on a screening compression 
Doppler ultrasound (CDU) or any symptomatic DVT in 
the popliteal or femoral veins, conﬁ rmed on imaging, 
within 30 days of randomisation. Evidence suggests that 
occurrence of DVT within the ﬁ rst month is associated 
with poorer functional outcomes at 6 months, even after 
adjustment for age, stroke severity, and leg weakness.21 
Secondary outcomes were, within 30 days, death, any 
DVT (including calf, popliteal, or femoral), symptomatic 
DVT, PE conﬁ rmed by imaging or autopsy, medical 
complications of GCS (eg, skin necrosis), and compliance 
with allocated treatment.
We aimed to undertake a CDU of the veins in both legs 
between days 7 and 10, and between days 25 and 30 after 
randomisation when practical. The decision not to do the 
second CDU was made and captured securely before 
randomisation—eg, if the patient was likely to be 
discharged home to another region or transferred to a 
rehabilitation facility that did not have Doppler facilities 
and was remote from the randomising centre. GCS were 
removed before the CDU to ensure optimum blinding of 
the investigators to the primary outcome measure. We 
obtained a hard copy of positive scans for central 
veriﬁ cation. We also accepted the results of any screening 
CDU done after 30 days; if these scans showed a popliteal 
or femoral DVT they were included in the primary 
outcome. Symptomatic DVTs detected more than 30 days 
after enrolment, other than on the planned screening 
CDU, were not included in the primary outcome to 
reduce ascertainment bias. A discharge form detailing 
Thigh-length GCS 
(n=1256)
Avoid GCS
(n=1262)
Overall
Age (years)* 76 (68–83) 76 (68–83)
Men 620 (49·4%) 622 (49·3%)
Final diagnosis at hospital discharge
Ischaemic stroke 1058 (84·2%) 1087 (86·1%)
Haemorrhagic stroke 132 (10·5%) 100 (7·9%)
Uncertain 39 (3·1%) 38 (3·0%)
Non-strokes (included in primary analysis) 24 (1·9%) 35 (2·8%)
Missing (no discharge form) 3 (0·2%) 2 (0·2%)
Past history and risk factors
Previous DVT or PE 55 (4·4%) 56 (4·4%)
Diabetes 191 (15·2%) 165 (13·1%)
Peripheral vascular disease 36 (2·9%) 26 (2·1%)
Overweight 320 (25·5%) 343 (27·2%)
Cigarette smoker 235 (18·7%) 235 (18·6%)
Independent in daily activities before stroke* 1145 (91·2%) 1152 (91·3%)
Lives alone before stroke* 443 (35·3%) 461 (36·5%)
Indicators of stroke severity
Able to lift both arms oﬀ  bed* 547 (43·5%) 558 (44·2%)
Able to talk and oriented in time, place, and person* 898 (71·5%) 890 (70·5%)
Able to lift both legs oﬀ  bed† 542 (43·1%) 550 (43·6%)
Able to walk without help* 0 (0%) 0 (0%)
Prescribed  heparin, warfarin, or alteplase at baseline† 98 (7·8%) 109 (8·6%)
Delay since stroke onset  to randomisation (0–1days)† 525 (41·8%) 511 (40·5%)
Stroke severity: probability of being alive and independent in 
daily activities 0–0·15†
660 (52·5%) 684 (54·2%)
Stroke severity: probability of being alive and independent in 
daily activities
0·14 (0·04–0·38) 0·12 (0·03–0·40)
Compression Doppler ultrasound at 30 days considered 
unlikely to be practical at time of  randomisation
351 (27·9%) 330 (26·1%)
Data are median (IQR) or number (%). GCS=graduated compression stockings. DVT=deep vein thrombosis. PE=pulmonary 
embolism. *Factors included in model to predict probability of being alive and independent at 6 months.20 †Variables 
included in minimisation.
Table 1: Baseline characteristics of patients enrolled into the CLOTS 1 trial
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in-hospital outcomes was completed for all randomised 
patients on discharge from the randomising centre or 
after death in hospital. We sent a postal questionnaire to 
every patients’ family doctor about 5·5 months after 
enrolment to establish the patients’ vital status, 
occurrence of DVTs or PE since hospital discharge, and 
any current use of oral anticoagulants. We followed up 
patients at 6 months after enrolment by postal 
questionnaire or telephone to ask whether they had had a 
DVT or PE after hospital discharge, and later secondary 
outcomes (to be reported elsewhere).
Statistical analysis
Initially we planned to recruit patients until we had 
identiﬁ ed 175 with our primary outcome. We estimated 
that we would need about 1500 patients to provide 90% 
power (α=0·05) to identify a 6% absolute reduction (from 
15% to 9%) in our primary outcome. In 2006, the steering 
committee, which was blind to any interim analysis that 
split patients by group allocation, decided to increase the 
power of the trial to detect a smaller treatment eﬀ ect of 
4% that was judged to be the smallest clinically-worthwhile 
beneﬁ t. The decision was made to recruit until December, 
2008, which was the latest that we could continue until 
and still complete follow-up within our funded period. By 
that time we expected to have recruited at least 
2200 patients, but had actually recruited 2518. The 
completed trial had 90% power to detect a 4% absolute 
risk reduction in our primary outcome.
The absolute diﬀ erence in the proportion of patients 
with a primary outcome between our allocated groups 
was calculated with 95% CIs. The proportions with a 
primary or secondary outcome were compared with odds 
ratios and 95% CIs. Results relating to the primary 
outcome were adjusted for three variables included in 
our minimisation algorithm (predicted stroke outcome, 
delay from stroke onset to randomisation, and ability of 
the patient to lift both legs oﬀ  the bed), and all analyses 
were based on intention to treat. Analyses of accumulating 
data were prepared by the trial statistician and reviewed 
at least once per year in strict conﬁ dence by the 
independent data monitoring committee. Preplanned 
subgroup analyses included our primary outcome 
subdivided by key baseline variables: time from stroke 
onset to randomisation (day 0 or 1 vs ≥2); use of 
antithrombotic agents (heparin, warfarin, or alteplase vs 
none); and paralysis of leg (able to lift both legs or not).
This study is registered, number ISRCTN28163533.
Role of the funding source
The sponsors of the study had no role in data collection, 
data storage, data analysis, preparation of this report, or 
the decision to publish. The UK Stroke Research Network 
(study ID 2133) adopted the trial in 2005, and much of 
the enrolment and data collection was undertaken by 
staﬀ  funded by the network or working for associated 
NHS organisations after that date. The corresponding 
author had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Figure 1 shows the trial proﬁ le and table 1 shows the 
patients’ baseline characteristics, which were well 
balanced between treatment groups.
Table 2 shows patient outcomes with respect to the 
primary and secondary endpoints. The use of thigh-length 
GCS was associated with a non-signiﬁ cant 0·5% 
(95% CI –1·9 to 2·9) absolute reduction in the primary 
outcome. The 95% CIs reliably exclude the smallest beneﬁ t 
that the trial steering committee considered clinically 
worthwhile. No important diﬀ erences occurred in any 
DVT (including symptomatic, asymptomatic, and below 
knee DVT) or in conﬁ rmed PE (table 2). Adverse eﬀ ects 
(eg, skin breaks, ulcers, blisters, and skin necrosis) were 
signiﬁ cantly more common in patients allocated to GCS 
than in those allocated to avoid GCS, and more patients 
allocated to GCS had lower limb amputation (seven vs 
two; table 2). Although most of these adverse events were 
probably directly caused by the GCS, the few amputations 
that arose usually resulted from apparent embolism 
causing acute limb ischaemia rather than being attributed 
to the direct eﬀ ect of stockings. However, the reporting of 
Thigh-length GCS 
(n=1256)
Avoid GCS 
(n=1262)
Odds ratio 
(95% CI)
Primary outcome
Proximal DVT 126 (10·0%) 133 (10·5%) ··
Alive and free of primary outcome 974 (77·5%) 1000 (79·2%) ··
Dead before any primary outcome 115 (9·2%) 101 (8·0%) ··
Missing 41 (3·3%) 28 (2·2%) ··
Unadjusted (dead and missing excluded) ·· ·· 0·97 (0·75-1·26)
Adjusted* (dead and missing excluded) ·· ·· 0·98 (0·76-1·27)
Secondary outcomes by 30 days or later second compression Doppler ultrasound
Dead by 30 days 122 (9·7%) 110 (8·7%) 1·13 (0·86–1·48)
Symptomatic proximal DVT 36 (2·9%) 43 (3·4%) 0·84 (0·53–1·31)
Asymptomatic proximal DVT 90 (7·2%) 90 (7·1%) 1·01 (0·74–1·36)
Symptomatic DVT (proximal or distal) 55 (4·4%) 61 (4·8%) 0·90 (0·62–1·31)
Any DVT (proximal or distal) 205 (16·3%) 224 (17·7%) 0·90 (0·73–1·11)
PE conﬁ rmed on imaging or autopsy 13 (1·0%) 20 (1·6%) 0·65 (0·32–1·31)
PE on autopsy 1 (0·1%) 1 (0·1%) 1·00 (0·06–16·08)
Any DVT or PE 213 (17·0%) 232 (18·4%) 0·91 (0·74–1·11)
Skin breaks/ulcers/blisters/skin necrosis 64 (5·1%) 16 (1·3%) 4·18 (2·40–7·27)
Lower limb ischaemia/amputation 7 (0·6%) 2 (0·2%) 3·53 (0·73–17·03)
Primary outcomes within 14 days
Post-hoc analysis restricting follow-up to 14 days† 87 (6·9%) 95 (7·5%) ··
Unadjusted (dead and missing excluded) ·· ·· 0·95 (0·70–1·28)
Adjusted* (dead and missing excluded) ·· ·· 0·95 (0·70–1·29)
Data are number (%) unless otherwise indicated. GCS=graduated compression stockings. DVT=deep vein thrombosis. 
PE=pulmonary embolism. *Adjusted for delay from onset to randomisation, stroke severity, and leg strength at 
baseline. †Full compliance by 14 days was 79·4% compared with 73·1% by 30 days.
Table 2: Primary and secondary outcomes
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adverse eﬀ ects was based on case-note review and was 
not blinded to treatment allocation. These data are 
therefore prone to ascertainment bias.
The results of our preplanned subgroup analyses do 
not suggest any signiﬁ cant interaction between subgroups 
and treatment eﬀ ect (ﬁ gure 2). Table 2 shows the results 
of some post-hoc analyses restricting follow-up to 14 days, 
which we undertook to try to understand why the 
stockings seemed to be ineﬀ ective in this acute stroke 
patient population. The risk of our primary outcome did 
not diﬀ er signiﬁ cantly between treatment groups when 
follow-up was limited to 14 days (the maximum duration 
in previous trials in surgical patients), during which time 
compliance with the thigh-length GCS was better than it 
was at 30-day follow-up (985 [79·4%] were fully 
compliant—ie, wore full-length GCS from randomisation 
to discharge from centre or earlier death or regained 
mobility—up to 14 days vs 916 [73·1%] up to 30 days).
Discussion
Findings from this study have shown that thigh-length 
GCS are not clinically eﬀ ective at reducing the risk of 
proximal DVT after stroke and are associated with some 
adverse eﬀ ects. This large trial included more patients 
and outcome events (proximal DVTs) than all previous 
randomised controlled trials of GCS combined. Patients 
were enrolled by 64 hospitals in three countries, and had 
similar baseline characteristics to those of patients 
admitted to hospitals in many diﬀ erent hospitals and 
countries, suggesting that our results have good external 
validity. Central randomisation, outcome-blinded 
assessment of our primary outcome, low losses to 
follow-up, and intention-to-treat analysis have kept bias 
to a minimum. Serious complications due to the GCS 
were rare, but their inconvenience and associated minor 
problems suggest these stockings should not be used 
unless they are associated with clinically signiﬁ cant 
beneﬁ ts. Recruitment in CLOTS trial 2, which was 
designed to establish whether thigh-length GCS are more 
eﬀ ective than below-knee GCS, has now been stopped 
because the results of this study suggest that exposure of 
patients with acute stroke to the discomfort, 
inconvenience, and risk of an ineﬀ ective treatment is not 
reasonable.
What might account for the absence of eﬀ ect in patients 
with stroke compared with the apparent eﬀ ectiveness 
shown by trials in patients undergoing surgery? The 
precision of our trial result is suﬃ  cient to make it very 
unlikely that we have missed a clinically worthwhile 
treatment eﬀ ect. We can reliably exclude an absolute 
reduction of 3% or greater, in a group of patients with an 
overall risk of proximal DVT of about 10% in untreated 
controls.
Trials in patients undergoing surgery have shown fairly 
convincingly that GCS applied before, during, and after a 
brief insult to the deep veins of the legs prevent DVTs, 
mainly in the calf.14 Only eight of the 17 trials in the 
systematic review reported the frequency of proximal 
DVT.14 Only nine of 435 (2%) patients allocated GCS and 
21 of 402 (5%) allocated to avoid GCS had a proximal 
DVT (odds reduction 60%; 95% CI 17–81; p=0·014).14 
However, although in the CLOTS trial 1 we did not 
systematically screen for DVTs in the distal veins, we did 
not record any evidence that GCS were more eﬀ ective in 
prevention of distal than proximal DVTs.
In patients with stroke, and those with other acute 
medical disorders, GCS can be applied only after the 
patient has become immobile. Immobility might then 
persist for weeks or even be permanent in such patients. 
DVTs can develop rapidly and cannot then be prevented 
as eﬀ ectively by a treatment starting a few days after the 
onset of paralysis and immobility. Clearly, we cannot test 
the eﬀ ectiveness of GCS applied before stroke onset; 
however, the absence of heterogeneity (ﬁ gure 2) between 
Figure 2: Frequency of the primary outcome by allocated treatment in the three prespeciﬁ ed subgroups
The ﬁ gure shows the point estimates of the odds ratio (adjusted for baseline factors) for each subgroup as a square (with size proportional to the amount of information) 
and the horizontal line depicts the 95% CIs. The open diamond indicates the adjusted odds ratio with 95% CI for all patients enrolled. The vertical line, at the odds ratio of 
unity, corresponds to the line of no eﬀ ect. Odds ratio values of less than unity correspond to a reduction in the primary outcome with graduated compression stockings 
(GCS). p values are for the interaction between the treatment eﬀ ect and the subgroup. Patients who died without previous deep vein thrombosis (DVT) and those without 
either Doppler are excluded from the denominators, which are therefore diﬀ erent to the total number allocated to each treatment group.
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patients enrolled on day 0–1 after stroke onset versus day 2 
and after does not provide evidence that this delay is 
crucial to the eﬀ ectiveness of GCS. 
GCS are thought to reduce the risk of DVT by several 
mechanisms: by increasing the velocity of venous blood 
by producing a pressure gradient in the leg, by reducing 
the cross-sectional area of the deep veins, and by making 
the calf muscle pump more eﬀ ective. This last mechanism 
might not operate in patients with stroke who have severe 
leg weakness, meaning that we might see less eﬀ ect in 
stroke patients with weak legs than in those with residual 
power. Although the absolute risk of proximal DVT was 
lower in the 1014 patients who were able to lift both their 
legs oﬀ  the bed at baseline than in those who could not 
(6·9% vs 15·5%), our ﬁ ndings did not show any 
signiﬁ cant interaction between the eﬀ ectiveness of GCS 
and these subgroups (ﬁ gure 2).
We could argue that patients with stroke but without 
signiﬁ cant leg weakness are more similar to immobile 
medical patients than are those undergoing surgery. The 
absence of eﬀ ect of GCS, even in the presence of some 
residual leg movement, suggests that the eﬀ ectiveness of 
GCS in acute medical patients cannot be assumed. 
Further trials in such patients are probably warranted.
Incorrect use and poor compliance with GCS might 
have reduced their eﬀ ectiveness. The manufacturers of 
the GCS used in this trial stress the importance of proper 
sizing and ﬁ tting of their stockings. Sizing depends on 
measurements of the calf and thigh circumferences and 
the leg length. There are 18 diﬀ erent sizes of thigh-length 
GCS and an additional ten with a suspender belt. In 
view of the complexity of achieving a good ﬁ t, a 
proportion of patients might have been given poorly 
ﬁ tting GCS in the trial. Compliance was good initially 
but reduced over time, mainly because patients found 
the GCS uncomfortable or staﬀ  became concerned by 
the condition of the patient’s skin. Nonetheless, overall 
compliance with the thigh-length GCS in this trial was 
reasonable, and we attempted to continue their use until 
the patient was discharged or regained mobility. Because 
of the training delivered to centres and the methods that 
we used to monitor compliance, we are conﬁ dent that 
sizing, ﬁ tting, and compliance within the trial were at 
least as good as in routine practice. In the randomised 
controlled trials in patients undergoing surgery, GCS 
were applied only for a few days, and screening for DVT 
was only done for a maximum of 14 days. Compliance in 
the CLOTS trial 1 was marginally better over the ﬁ rst 
14 days than over 30 days, but we did not note any greater 
eﬀ ect when we restricted our analyses to events occurring 
in the ﬁ rst 14 days (table 2).
With the assumption that the results of the CLOTS 
trial 2 (which will be available in late 2009) will not show 
an unexpected result (that below-knee stockings are more 
eﬀ ective than are thigh-length ones), this trial provides 
no evidence to support the routine use of GCS in 
immobile, hospitalised patients with acute stroke. 
National stroke guidelines that recommend their use 
might now need to be updated as a result of this new 
evidence. In view of the absence of net beneﬁ t from 
heparin or low-molecular-weight heparin in ischaemic 
stroke,3 future research with data available from this and 
other trials needs to establish whether there are speciﬁ c 
subgroups of patients, who are at greater than average 
risk of venous thromboembolism and low risk of bleeding 
complications, who might gain net beneﬁ t from 
anticoagulation. Hopefully, the CLOTS trial 3 will 
establish whether intermittent pneumatic compression, 
which does not have associated bleeding risks and can be 
therefore used in haemorrhagic and ischaemic stroke, is 
eﬀ ective in reducing the risk of DVT after stroke.
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